Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (yeni pencere açar)

CRASH-3 Trial Collaborators

Kaynak‎: Lancet 2019;394(10210):1713-23.

İndeks‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (yeni pencere açar)

Alternatives to allogeneic platelet transfusion. (yeni pencere açar)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Kaynak‎: Br J Haematol 2016;175(3):381-92.

İndeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (yeni pencere açar)

Tranexamic acid: less bleeding and less thrombosis? (yeni pencere açar)

Godier A, Roberts I, Hunt BJ.

Kaynak‎: Crit Care 2012;16(3):135.

İndeks‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (yeni pencere açar)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (yeni pencere açar)

Perel P, Ker K, Morales Uribe CH, Roberts I

Kaynak‎: Cochrane Database Syst Rev 2013;(1):CD010245.

İndeks‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (yeni pencere açar)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (yeni pencere açar)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Kaynak‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

İndeks‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (yeni pencere açar)

Antifibrinolytic drugs for acute traumatic injury. (yeni pencere açar)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Kaynak‎: Cochrane Database Syst Rev 2011;(1):CD004896.

İndeks‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (yeni pencere açar)

Use of tranexamic acid to reduce bleeding in burns surgery. (yeni pencere açar)

Tang YM, Chapman TW, Brooks P

Kaynak‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

İndeks‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (yeni pencere açar)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (yeni pencere açar)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Kaynak‎: Burns. 2022;48(3):522-28.

İndeks‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (yeni pencere açar)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (yeni pencere açar)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Kaynak‎: J Blood Med 2011;2:131-4.

İndeks‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (yeni pencere açar)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (yeni pencere açar)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Kaynak‎: Transfusion 2009;49 Suppl 5:240S-7S.

İndeks‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (yeni pencere açar)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (yeni pencere açar)

Fries D

Kaynak‎: Transfusion 2013;53 Suppl 1:91S-5S.

İndeks‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (yeni pencere açar)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (yeni pencere açar)

Haan J, Scalea T

Kaynak‎: Am Surg 2005;71(5):414-5.

İndeks‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (yeni pencere açar)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (yeni pencere açar)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Kaynak‎: J Trauma 2010;69(3):489-500.

İndeks‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (yeni pencere açar)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (yeni pencere açar)

Hsia CC, Chin-Yee IH, McAlister VC.

Kaynak‎: Ann Surg 2008;248(1):61-8.

İndeks‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (yeni pencere açar)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (yeni pencere açar)

Johansson PI, Eriksen K, Alsbjørn B

Kaynak‎: J Trauma 2006;61(4):1016-8.

İndeks‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (yeni pencere açar)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (yeni pencere açar)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Kaynak‎: ANZ J Surg 2013;83(3):155-60.

İndeks‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (yeni pencere açar)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (yeni pencere açar)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Kaynak‎: Injury 2012;43(9):1409-14.

İndeks‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (yeni pencere açar)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (yeni pencere açar)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Kaynak‎: Injury 2008;39(9):1054-61.

İndeks‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (yeni pencere açar)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (yeni pencere açar)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Kaynak‎: Anesthesiology 2003;98(6):1513-5.

İndeks‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (yeni pencere açar)

Alternatives to allogeneic platelet transfusion. (yeni pencere açar)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Kaynak‎: Br J Haematol 2016;175(3):381-92.

İndeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (yeni pencere açar)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (yeni pencere açar)

Fries D

Kaynak‎: Transfusion 2013;53 Suppl 1:91S-5S.

İndeks‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (yeni pencere açar)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (yeni pencere açar)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Kaynak‎: Thromb Res 2014;134(2):360-8.

İndeks‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (yeni pencere açar)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (yeni pencere açar)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Kaynak‎: Br J Haematol 2013;160(2):228-36.

İndeks‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (yeni pencere açar)

Strategies to reduce the use of blood products: a European perspective. (yeni pencere açar)

Theusinger OM, Felix C, Spahn DR.

Kaynak‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

İndeks‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (yeni pencere açar)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (yeni pencere açar)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Kaynak‎: Anesthesiology 2008;109(6):1063-76.

İndeks‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (yeni pencere açar)

Alternatives to allogeneic platelet transfusion. (yeni pencere açar)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Kaynak‎: Br J Haematol 2016;175(3):381-92.

İndeks‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (yeni pencere açar)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (yeni pencere açar)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Kaynak‎: Blood Rev 2014;28(3):95-102.

İndeks‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (yeni pencere açar)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (yeni pencere açar)

Alperin JB

Kaynak‎: JAMA 1987;258(14):1916-9.

İndeks‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (yeni pencere açar)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (yeni pencere açar)

Crowther MA, McDonald E, Johnston M, Cook D

Kaynak‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

İndeks‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (yeni pencere açar)

The use of fibrin sealant in burn operations. (yeni pencere açar)

Foster K

Kaynak‎: Surgery 2007;142(4 Suppl):S50-4.

İndeks‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (yeni pencere açar)

Use of fibrin sealant in thermal injury. (yeni pencere açar)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Kaynak‎: J Burn Care Rehabil 1997;18(5):429-34.

İndeks‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (yeni pencere açar)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (yeni pencere açar)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Kaynak‎: Br J Anaesth 2012;109(3):376-81.

İndeks‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (yeni pencere açar)

Transfusion in trauma: why and how should we change our current practice? (yeni pencere açar)

Theusinger OM, Spahn DR, Ganter MT.

Kaynak‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

İndeks‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (yeni pencere açar)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (yeni pencere açar)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Kaynak‎: Health Technol Assess 2015;19(58):1-228.

İndeks‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (yeni pencere açar)